Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· November 28, 2025

Stock market today: S&P 500, Dow rise to end a rocky month, Nasdaq snaps 7-month win streak

View original at finance.yahoo.com
Stock market today: S&P 500, Dow rise to end a rocky month, Nasdaq snaps 7-month win streak US stocks rose during a holiday-shortened trading day on Friday as a volatile month drew to a close and the Nasdaq Composite (^IXIC) snapped a seven-month win streak…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • S&P 500 will hover around 7,500 by end of 2026

    80% confidence
  • S&P 500 will reach 8,000 by end of 2026

    80% confidence
  • Government has tremendous deficit, tremendous government spending, and tremendous central bank buying supporting gold prices

    80% confidence
  • Expects Black Friday to kick off a strong holiday shopping season with consumers spending $253 billion

    80% confidence
  • Companies missing Q3 earnings estimates saw stock decrease of 5% on average, well below five-year average decrease of 2.6%

    80% confidence
  • Consumers spent $6 billion on Thanksgiving Day

    80% confidence
  • S&P 500 will hover around 7,500 by end of 2026

    80% confidence
  • S&P 500 companies reporting Q3 earnings beats saw stock price increase of 0.4% on average in four-day period around earnings release, below five-year average of 0.9%

    80% confidence
  • Oracle faces credit market concerns that will worsen in 2026 unless Oracle can reassure investors about AI spending

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com